Quick Answer
Immunovant, Inc. reported Total Assets of $776.22 million for fiscal year 2025.
Immunovant, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $776.22M | +16.5% |
| 2024 | $666.37M | +64.2% |
| 2023 | $405.84M | -21.3% |
| 2022 | $515.56M | +25.0% |
| 2021 | $412.49M | +277.1% |
| 2020 | $109.39M | +691.1% |
| 2019 | $13.83M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $1.05B | +150.0% | +80.5% |
| September 30, 2025 | $582.96M | +13.0% | -11.9% |
| June 30, 2025 | $661.44M | +12.2% | -14.8% |
| March 31, 2025 | $776.22M | +16.5% | +84.4% |
| December 31, 2024 | $420.93M | -40.8% | -18.4% |
| September 30, 2024 | $515.71M | +76.6% | -12.5% |
| June 30, 2024 | $589.68M | +67.9% | -11.5% |
| March 31, 2024 | $666.37M | +64.2% | -6.3% |
- Immunovant, Inc. showed an increase of +16.5% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Immunovant, Inc.’s total assets has grown by 5513.4% (from $13.83 million to $776.22 million).
- The most recent figure is from Immunovant, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: